ProCE Banner Activity

AtezoTRIBE: Updated Results of First-line Treatment With FOLFOXIRI + Bevacizumab ± Atezolizumab for Unresectable Metastatic Colorectal Cancer

Conference Coverage
Slideset

Addition of atezolizumab to FOLFOXIRI plus bevacizumab as initial therapy prolongs PFS in molecularly unselected mCRC patients.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen